Clearmind Medicine Inc., a company listed in the United States, received a comment from the Securities and Exchange Commission (SEC) regarding its Form 20-F filing for the fiscal year ended October 31, 2023. The SEC's correspondence, dated March 21, 2024, addressed to Chief Financial Officer Alan Rootenberg, noted the absence of required certifications by the company's principal executive officer and principal financial officer in the amendment No.1 to the Form 20-F. The SEC has requested that Clearmind Medicine amend its filing to include the updated certifications as per the Securities Exchange Act of 1934 Rule 13a-14(b) and Rule 15d-14(b), referencing the amendment. The SEC has asked for a response within ten business days or an advisory on when the company will be able to respond. The communication also mentioned that further comments may follow after the review of the company's response to this letter.

Clearmind Medicine Inc., a company listed in the United States, received a comment from the Securities and Exchange Commission (SEC) regarding its Form 20-F filing for the fiscal year ended October 31, 2023. The SEC's correspondence, dated March 21, 2024, addressed to Chief Financial Officer Alan Rootenberg, noted the absence of required certifications by the company's principal executive officer and principal financial officer in the amendment No.1 to the Form 20-F. The SEC has requested that Clearmind Medicine amend its filing to include the updated certifications as per the Securities Exchange Act of 1934 Rule 13a-14(b) and Rule 15d-14(b), referencing the amendment. The SEC has asked for a response within ten business days or an advisory on when the company will be able to respond. The communication also mentioned that further comments may follow after the review of the company's response to this letter.